摘要
目的:探讨芪归四逆散辅佐治疗肝郁脾虚血瘀型慢性乙型肝炎纤维化临床疗效。方法:选取我中心诊治的60例肝郁脾虚血瘀型慢性乙型肝炎患者为研究对象,采用信封分组法将患者分为联合组和常规组,联合组在常规组恩替卡韦分散片治疗基础上采用芪归四逆散辅佐治疗,比较两组患者治疗前后肝纤维化指标及临床疗效。结果:治疗前两组患者HA、PCⅢ、LN水平比较无统计学意义(P>0.05);治疗后联合组患者HA、PCⅢ、LN水平均低于常规组,两组比较差异均有统计学意义(P均<0.01)。联合组患者治疗总有效率显著高于常规组(96.67%∶76.67%,P<0.05)。结论:芪归四逆散辅佐恩替卡韦分散片治疗肝郁脾虚血瘀型慢性乙型肝炎肝纤维化患者能显著改善患者肝纤维化状态,提高临床疗效。
Objective： To discuss the clinical efficacy of qigui sannisan on the ajuvant treatment of liver fibrosis of chronic hepatitis B patients with liver depression and spleen deficiency and blood stasis syndrome. Methods： 60 cases of liver and spleen deficiency and blood stasis of chronic hepatitis B patients in our center were selected as the subjects,who were divided into the combined group and conventional group with envelope grouping. The combined group was ajuvantly treated with qigui sannisan on the basis of the administered entecavir dispersible tablets in the conventional group,then the efficacy and hepatic fibrosis markers of both groups before and after the treatment were compared. Results： There were no significant differences of the level of HA,PC Ⅲ and LN between the both groups before treatment（ P〈0.01）,but the level of HA,PCⅢ and LN of the combined group were lower than that of the conventional group（ P〈0. 05）. The total effective rate of the combined group was significantly higher than of the conventional group（ 96.67% vs.76.67%,P〈0.05）. Conclusion： Ajuvant treatment with qigui sinisan and entecavir dispersible tablets can significantly improve the efficacy and condition of qigui liver fibrosis in patients with chronic hepatitis B with liver depression,spleen deficiency and blood stasis.
出处
《华夏医学》
CAS
2017年第4期76-79,共4页
Acta Medicinae Sinica
关键词
肝郁脾虚血瘀型
慢性乙型肝炎
肝纤维化
芪归四逆散
恩替卡韦分散片
liver and spleen deficiency and blood stasis
chronic hepatitis B
liver fibrosis
qigui sinisan
entecavir dispersible tablets
